Previous 10 | Next 10 |
Amarin ( NASDAQ: AMRN ) is licensing exclusive rights to Vazkepa to CSL Seqirus to secure pricing and reimbursement, and sell the heart drug in Australia and New Zealand. Under the agreement, Amarin will receive an upfront payment and be eligible for event-related miles...
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive...
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today issued the following statement in response to Sarissa’s latest misstatements regarding the Company’s managemen...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data evaluating the role of VASCEPA ® /VAZKEPA ® (icosapent ethyl) and eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk pati...
Sarissa believes Amarin board acted in bad faith by making these equity grants while refusing to disclose proxy contest results and will hold each director personally accountable Sarissa urges Amarin CEO Karim Mikhail to repudiate his undeserved equity grants and re-issue them to hard wor...
Summary Amarin and Sarissa are engaged in a bitter proxy war. Amarin has problems, but Sarissa doesn't have clear solutions. Amarin has given considerable proof of how its new management performed in the last few quarters. Amarin ( AMRN ) and Sarissa are engaged in a m...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference. Cowen Annual Hea...
Sarissa Capital’s board candidates will represent shareholders and help create value at Amarin during this critical period Sarissa Capital believes removing Chairman Per Wold-Olsen from the Amarin board is in shareholders’ best interest Sarissa Capital Management L...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s fourth quarter and year end 2022 financial resul...
Sarissa believes Amarin leadership will continue to destroy shareholder value during this critical period; We cannot afford to maintain the status quo Sarissa has a stellar track record of success and its nominees have the experience and qualifications to help fix the problems at Amarin ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
2024-07-31 14:15:16 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q2 2024 Earnings Call Jul 31, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
Dayforce Inc. (DAY) is expected to report $0.18 for Q2 2024 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.44 for Q2 2024 Aurora Innovation Inc. (AUR) is expected to report for Q2 2024 Autohome Inc. American Depositary Shares each repr...
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...